Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Iovance Biotherapeutics Inc. (NASDAQ: IOVA ) is one of the most promising penny stocks under $5 to buy . On February 24, Iovance Biotherapeutics reported earnings for Q4 and the full year 2025, highlighted by a 61% year-over-year increase in total annual revenue to $264 million. Q4 alone generated $87 million in product revenue, representing 30% growth over the previous quarter. This growth was largely driven by the success of Amtagvi, which saw a 112% increase in year-over-year revenue, alongside improved operational efficiency. On the clinical and regulatory front, Iovance achieved several milestones that support its long-term outlook. The FDA granted Fast Track Designation for lifileucel in non-small cell lung cancer, a move that validates current clinical data and supports a projected 2027 launch for that indication. Additionally, the company reported a promising 50% confirmed response rate in advanced soft tissue sarcomas, with data showing that patient responses are deepening
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.MarketBeat
- Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- IOVA's page on the SEC website